What question did this study set out to answer?

To compare the antitumor efficacy of tumor-specific CD4 T cells versus CD8 cytotoxic T lymphocytes across various tumor models.

February 28, 2007BloodOpen Access

CD4 cells can be more efficient at tumor rejection than CD8 cells

View Full Paper

Ask AI

Bookmark

To compare the antitumor efficacy of tumor-specific CD4 T cells versus CD8 cytotoxic T lymphocytes across various tumor models.
Transferred monoclonal populations of tumor-specific CD4 or CD8 T cells into mouse models bearing distinct tumors.
Assessed tumor rejection across tumors expressing MHC class I without MHC class II, evaluating the requirement of host MHC class II and NK cell cooperation.
CD4 T cells completely eradicated tumors that were refractory to CD8-mediated rejection, even when the tumors expressed MHC class I but lacked MHC class II.
Maximal antitumor activity depended on host MHC class II expression and direct cooperation between CD4 T cells and host natural killer cells.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Mouse study reveals that tumor-specific CD4 T cells eliminate CD8-resistant tumors with natural killer cells, indicating a potent effector role in immunotherapy.

Cite This Study

Pérez‐Díez et al. (2007) studied this question.

synapsesocial.com/papers/6a1f57c6da07783dec23539f https://doi.org/10.1182/blood-2006-10-051318

View Full Paper

Ask AI

Bookmark

Implication

Mouse study reveals that tumor-specific CD4 T cells eliminate CD8-resistant tumors with natural killer cells, indicating a potent effector role in immunotherapy.

CD4 cells can be more efficient at tumor rejection than CD8 cells

Key Points

Discussion

Implication

Cite This Study

CD4 cells can be more efficient at tumor rejection than CD8 cells

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading